SPYRE THERAPEUTICS INC (SYRE) Stock Analyst Ratings
NASDAQ:SYRE - Nasdaq - US00773J2024 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 89% to SYRE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 55.42. This target is 220.53% above the current price.
SYRE was analyzed by 18 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about SYRE.
In the previous month the buy percentage consensus was at a similar level.
SYRE was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-08 | Leerink Partners | Initiate | Outperform |
| 2024-12-11 | Jones Trading | Initiate | Hold |
| 2024-11-13 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-25 | Guggenheim | Maintains | Buy -> Buy |
| 2024-09-04 | Wedbush | Initiate | Outperform |
| 2024-07-16 | Evercore ISI Group | Initiate | Outperform |
| 2024-05-13 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-05-10 | BTIG | Maintains | Buy -> Buy |
| 2024-05-02 | Baird | Initiate | Outperform |
| 2024-03-26 | Stifel | Reiterate | Buy -> Buy |
| 2024-03-01 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
| 2023-12-20 | BTIG | Initiate | Buy |
| 2023-12-18 | Stifel | Maintains | Buy -> Buy |
| 2023-12-11 | Guggenheim | Initiate | Buy |
| 2023-12-11 | Jefferies | Initiate | Buy |
| 2023-11-29 | TD Cowen | Initiate | Outperform |